Trial
NCT02106520
Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hospices Civils de Lyon
Collaborators
—
Condition
Hereditary Hemorrhagic Telangiectasia
Intervention
Bevacizumab
Why stopped
DSMB's decision following the first step analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-20